Meiß, Frank 1975-
Meiß, Frank Roland 1975-
Frank Meiss researcher (ORCID 0000-0002-4044-9094)
VIAF ID: 20745535 (Personal)
Permalink: http://viaf.org/viaf/20745535
Preferred Forms
4xx's: Alternate Name Forms (5)
5xx's: Related Names (2)
Works
Title | Sources |
---|---|
Additive intralesional interleukin-2 improves progression-free survival in a distinct subgroup of melanoma patients with prior progression under immunotherapy | |
Adult‐Onset Neurodegeneration in Nucleotide Excision Repair Disorders (NERDND): Time to Move Beyond the Skin | |
Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin-integrin-[beta]1expression | |
Case report: blurred vision and eruptive nevi - bilateral diffuse uveal melanocytic proliferation with mucocutaneous involvement in a lung cancer patient | |
Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma | |
Combinatorial effects of azacitidine and trametinib on NRAS‐mutated melanoma | |
Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature | |
efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma : a retrospective multicenter study | |
eHealth literacy in German skin cancer patients | |
Hemidesmosomal reactivity and treatment recommendations in immune checkpoint inhibitor-induced bullous pemphigoid - a retrospective, monocentric study | |
IL17 inhibition for psoriasis vulgaris and arthritis results in clinical and serological remission of coexistent pemphigus foliaceus: letter to the editor | |
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG | |
Incidence and severity of immune-related hepatitis after dual checkpoint therapy is linked to younger age independent of herpes virus immunity | |
Is there an overtreatment of melanoma patients at the end of their life? Results of a multicenter study on 193 melanoma patients | |
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study | |
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma – an evaluation of the multicenter prospective skin cancer registry ADOREG | |
Personalized clinical decision making through implementation of a molecular tumor board: a German single-center experience | |
Personalized treatment selection and disease monitoring using circulating tumor DNA profiling in real-world cancer patient management | |
Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial) | |
Real world outcomes using PD‐1 antibodies and BRAF+ MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland | |
S2k‐Leitlinie – Kutane Lymphome (ICD10 C82–C86): Update 2021 | |
Small-vessel vasculitis after ST-segment elevation myocardial infarction | |
Targeting of cell surface proteolysis of collagen XVII impedes squamous cell carcinoma progression | |
Technische Fehler bei der Platzierung von Pedikelschrauben in der minimalinvasiven computerunterstützten Wirbelsäulenchirurgie | |
Untersuchungen zum Einfluß des arteriellen Leberblutflusses und von Sauerstoff auf die Leberfunktion bei Patienten mit Zirrhose | |
value of primary and adjuvant radiotherapy for cutaneous squamous cell carcinomas of the head-and-neck region in the elderly | |
Variable outcome of immunotherapy in advanced multiple cutaneous squamous cell carcinomas in two patients with recessive dystrophic epidermolysis bullosa |